The mRNA expression of BCL2L1 and MET was increased after ginsenoside Rg3, ginsenoside Rg5, and pseudoginsenoside F11 treatment, indicating that these three components may protect cardiomyocytes from damage by inhibiting apoptosis to improve heart failure. Here, BCL2L1 is linked to heart failure.